You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
McKinsey
Colorcon
Boehringer Ingelheim
AstraZeneca

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Varespladib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Varespladib?

Varespladib is an investigational drug.

There have been 8 clinical trials for Varespladib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2010.

The most common disease conditions in clinical trials are Syndrome, Anemia, Sickle Cell, and Acute Coronary Syndrome. The leading clinical trial sponsors are Anthera Pharmaceuticals, Rawalpindi Institute of Cardiology, and University Health Network, Toronto.

There are thirty-four US patents protecting this investigational drug and three hundred and ninety-eight international patents.

Recent Clinical Trials for Varespladib
TitleSponsorPhase
Effect of Colchicine in Patients With Myocardial InfarctionRawalpindi Institute of CardiologyPhase 2
Effect of Colchicine in Patients With Myocardial InfarctionShifa Tameer-e-Millat UniversityPhase 2
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.Anthera PharmaceuticalsPhase 2

See all Varespladib clinical trials

Clinical Trial Summary for Varespladib

Top disease conditions for Varespladib
Top clinical trial sponsors for Varespladib

See all Varespladib clinical trials

US Patents for Varespladib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Varespladib   Start Trial Method and composition for preventing NSAID-induced renal failure E. I. Du Pont de Nemours and Company (Wilmington, DE)   Start Trial
Varespladib   Start Trial Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists E. I. Du Pont de Nemours and Company (Wilmington, DE)   Start Trial
Varespladib   Start Trial 1H-indole-3-glyoxylamide SPLA.sub.2 inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
Varespladib   Start Trial Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles Merck & Co., Inc. (Rahway, NJ)   Start Trial
Varespladib   Start Trial 1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Varespladib

Drugname Country Document Number Estimated Expiration Related US Patent
Varespladib Austria 113276 2006-07-11   Start Trial
Varespladib Austria 134368 2006-07-11   Start Trial
Varespladib Austria 146076 2006-07-11   Start Trial
Varespladib Austria 151755 2006-07-11   Start Trial
Varespladib Austria 164520 2006-07-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Moodys
Dow
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.